Survival Analysis of Postoperative Adjuvant Chemotherapy for Stage IB Non‐Small Cell Lung Cancer Based on Racial Stratification

The survival benefits of adjuvant chemotherapy for stage IB non‐small cell lung cancer (NSCLC) remain controversial. The existing evidence is mostly based on the Caucasian population, especially the differences in efficacy among different races are not yet clear.

• Publication year

  2025

• Venue

  ANZ journal of surgery

• Publication date

  2025-09-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/ans.70317PMID 40904175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of histopathological subtypes on invasive lung adenocarcinoma: from epidemiology to tumour microenvironment to therapeutic strategies

  2025cited by this paper
• Perioperative Treatment in EGFR‐Mutant Early‐Stage Non‐Small Cell Lung Cancer: Current Evidence and Future Perspectives

  2025cited by this paper
• Genomic landscape of cancer in racially and ethnically diverse populations

  2024cited by this paper
• The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.

  2024cited by this paper
• The global burden of lung cancer: current status and future trends

  2023cited by this paper
• Value of adjuvant chemotherapy for patients with pT2N0M0 non‐small cell lung cancer receiving radical resection

  2023cited by this paper
• Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma

  2023cited by this paper
• Sociodemographic survival disparities for lung cancer in the United States, 2000-2016.

  2022cited by this paper
• Race is a key determinant of the human intratumor microbiome.

  2022cited by this paper
• Ethnic inequalities in routes to diagnosis of cancer: a population-based UK cohort study

  2022cited by this paper
• Patient-derived xenograft (PDX) models, applications and challenges in cancer research

  2022cited by this paper
• Differences in cancer incidence by broad ethnic group in England, 2013–2017

  2022cited by this paper
• Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer

  2022cited by this paper
• Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study

  2021cited by this paper
• Advances in systemic therapy for non-small cell lung cancer

  2021cited by this paper
• Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis

  2021cited by this paper
• Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion

  2020influential reference
• Genomic landscape of lung adenocarcinoma in East Asians

  2020cited by this paper
• Advances in Systemic Therapy for Non-Small Cell Lung Cancer

  2020cited by this paper
• Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

  2020cited by this paper
• Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer

  2019cited by this paper
• The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients

  2019cited by this paper
• Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

  2018cited by this paper
• Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First‐Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung — A Multicenter, Open‐label, Randomized, Phase III Trial

  2018cited by this paper
• Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2017cited by this paper
• Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry

  2016cited by this paper
• The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient

  2015cited by this paper
• Adjuvant chemotherapy for resected early-stage non-small cell lung cancer.

  2015cited by this paper
• Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer

  2013cited by this paper
• DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy

  2010cited by this paper
• Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

  2010cited by this paper
• Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

  2008cited by this paper
• Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.

  2008cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

  2006cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

  2004cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

  1995cited by this paper
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

  1995cited by this paper

• No citing papers are available for this paper.